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Nicotinamide suppresses hyperphosphatemia in hemodialysis
patients.
Background. The use of calcium- or aluminum-based phos-
phate binders against hyperphosphatemia is limited by the ad-
verse effects of hypercalcemia or aluminum toxicity in long-
term hemodialysis. Because nicotinamide is an inhibitor of
sodium-dependent phosphate cotransport in rat renal tubule
and small intestine, we examined whether nicotinamide reduces
serum levels of phosphorus and intact parathyroid hormone
(iPTH) in patients undergoing hemodialysis.
Methods. Sixty-five hemodialysis patients with a serum phos-
phorus level of more than 6.0 mg/dL after a 2-week washout of
calcium carbonate were enrolled in this study. Nicotinamide was
administered for 12 weeks. The starting dose was 500 mg/day,
and the dose was increased by 250 mg/day every 2 weeks un-
til serum phosphorus levels were well controlled at less than
6.0 mg/dL. A 2-week posttreatment washout period followed
the cessation of nicotinamide. Blood samples were collected ev-
ery week for measurement of serum calcium, phosphorus, lipids,
iPTH, and blood nicotinamide adenine dinucleotide (NAD).
Results. The mean dose of nicotinamide was 1080 mg/day.
The mean blood NAD concentration increased from 9.3 ±
1.9 nmol/105 erythrocytes before treatment to 13.2 ± 5.3 nmol/
105 erythrocytes after treatment (P < 0.01). The serum phos-
phorus concentration increased from 5.4 ± 1.5 mg/dL to 6.9 ±
1.5 mg/dL with the pretreatment washout, then decreased to
5.4 ± 1.3 mg/dL after the 12-week nicotinamide treatment (P <
0.0001), and rose again to 6.7 ± 1.6 mg/dL after the posttreat-
ment washout. Serum calcium levels decreased during the pre-
treatment washout from 9.1 ± 0.8 mg/dL to 8.7 ± 0.7 mg/dL with
the cessation of calcium carbonate. No significant changes in
serum calcium levels were observed during nicotinamide treat-
ment. Median serum iPTH levels increased with pretreatment
washout from 130.0 (32.8 to 394.0) pg/mL to 200.0 (92.5 to 535.0)
pg/mL and then decreased from the maximum 230.0 (90.8 to
582.0) pg/mL to 150.0 (57.6 to 518.0) pg/mL after the 12-week
nicotinamide treatment (P < 0.05). With nicotinamide, serum
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high-density lipoprotein (HDL) cholesterol concentrations in-
creased from 47.4 ± 14.9 mg/dL to 67.2 ± 22.3 mg/dL (P <
0.0001) and serum low-density lipoprotein (LDL) cholesterol
concentrations decreased from 78.9 ± 18.8 mg/dL to 70.1 ±
25.3 mg/dL (P < 0.01); serum triglyceride levels did not change
significantly.
Conclusion. Nicotinamide may provide an alternative for
controlling hyperphosphatemia and hyperparathyroidism with-
out inducing hypercalcemia in hemodialysis patients.
End-stage renal disease (ESRD) is associated with cal-
cium and phosphate metabolism abnormalities that can
result in severe bone disease and ectopic calcification of
cardiovascular tissues [1, 2]. Phosphorus-restricted diets
are essential for the prevention of these deleterious com-
plications in ESRD patients. Weekly dietary absorption
of phosphate is approximately 4200 mg, assuming frac-
tional absorption of phosphate is 60% [3], whereas phos-
phate efflux is approximately 1057 mg per 4-hour dialysis
session or 3171 mg per week [4], suggesting a positive
phosphorus balance in dialysis patients. The common
phosphate binders contain aluminum or calcium. Alu-
minum accumulates in the tissues and causes neurologic,
skeletal, and hematologic toxicities [5, 6]. Ingestion of
calcium carbonate, an effective phosphate binder, leads
to hypercalcemia and increases the risk of vascular calci-
fication in ESRD patients [7, 8].
Nicotinamide is a circulating form of nicotinic acid.
The biologic function of nicotinamide derives from its
active form, nicotinamide adenine dinucleotide (NAD).
Administration of nicotinamide is reported to increase
the concentration of renal cortical tissue NAD, which was
shown to inhibit phosphate uptake by brush border mem-
brane vesicles obtained from rat proximal tubules [9, 10].
A similar effect of nicotinamide has been reported on
phosphate uptake by brush border membrane vesicles
isolated from the rat small intestine [11], suggesting that
nicotinamide is probably an effective inhibitor of phos-
phorus absorption in the intestine.
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Table 1. Baseline characteristics of study patients (N = 65)
Gender males/females 38/27
Age years 57.0 ± 11.5
Vitamin D users/nonusers 17/48
Time on dialysis years 6.5 ± 5.2
Etiology of end-stage renal disease
Chronic glomerulonephritis 31
Diabetes mellitus 24
Hypertension 5
Polycystic kidney disease 3
Other 2
Laboratory values
Serum phosphorus mg/dL 5.4 ± 1.5
Serum calcium mg/dL 9.1 ± 0.8
Serum calcium-phosphorus product mg2/dL2 48.4 ± 13.6
Serum intact parathyroid hormone pg/mL 187.3 ± 204.4
Numbers are number of patients unless otherwise indicated.
The aim of the present study was to examine whether
nicotinamide lowers serum levels of phosphorus and in-
tact parathyroid hormone (iPTH) in long-term hemodial-
ysis patients.
METHODS
Seventy-two hemodialysis patients were originally en-
rolled in the present study. All patients had been dialyzed
three times weekly with a bicarbonate dialysate for 6.5 ±
5.2 years. The dialysate calcium concentration was 3.0
mEq/L. Patients with a history of serious gastrointestinal
disease, malignancy, total parathyroidectomy, vasculitis,
dementia, or poorly controlled diabetes mellitus were ex-
cluded. Inclusion criteria were stable dosage of calcium
carbonate (2.9 ± 1.7 g/day) for at least 1 month and avoid-
ance of intentional changes in diet throughout the study.
Seventeen patients were being given vitamin D (0.4 ± 0.2
lg/day) at the start of the study. No changes in the dosage
of vitamin D were made during the study.
We obtained written informed consent from each par-
ticipant, and the study protocol was approved by the Hu-
man Research Ethics Committee of the Koto Hospital.
Administration of calcium carbonate was discontinued
during a 2-week pretreatment washout period (weeks
−2 to 0). Sixty-five hemodialysis patients (38 men and
27 women; mean age, 57.0 years) with serum phosphorus
levels of more than 6.0 mg/dL during the pretreatment
washout period were eligible for nicotinamide treatment.
Characteristics of these patients are shown in Table 1. The
65 patients received nicotinamide (Nippon Roche K.K.,
Tokyo, Japan) for 12 weeks (weeks 1 to 12). The starting
dose of nicotinamide was 500 mg/day and was increased
by 250 mg/day every 2 weeks if necessary to control the
serum phosphorus concentration at less than 6.0 mg/dL.
The nicotinamide was given twice daily in powder form
immediately after meals. After 12 weeks of treatment,
the patients were taken off nicotinamide (weeks 13 to 14,
posttreatment washout period).
Blood samples were collected weekly prior to a
hemodialysis session, and serum concentrations of phos-
phorus, calcium, and lipids were determined by standard
clinical laboratory methods. The serum iPTH concentra-
tion was determined by immunochemilumetric assay (In-
tact PTH Kit) (Nichols Institute Diagnostics, San Juan
Capistrano, CA, USA) (upper limit of normal, 65 pg/mL).
The blood NAD concentration was determined accord-
ing to the Shibata and Murata–modified [12] Nisselbaum
and Green method [13]. Blood NAD concentrations were
expressed as NAD per 105 erythrocytes (nmol/105 ery-
throcytes) because NAD was not detected in serum. Di-
etary intake was estimated every 2 weeks as the protein
catabolic rate (PCR) [14]. We judged the avoidance of
intentional changes in diet by no change in PCR. Com-
pliance was confirmed by face-to-face interview.
Data are expressed as mean ± standard deviation (SD)
or as median values when the data were highly skewed.
The Wilcoxon signed-rank test was used to analyze differ-
ences in paired group data. The effects of nicotinamide
administration on the serum phosphorus concentrations
and other laboratory values were assessed by comparing
the serum levels at the end of the pretreatment washout
period to those at the end of the treatment period.
Spearman’s rank correlation coefficient was calculated
to assess association between the changes in serum phos-
phorus and other laboratory values. Statistical analyses
were based on two-tailed Student t test. iPTH levels were
shown as median (10th to 90th percentile) and expressed
as box and whisker plots. The analysis of PTH data was
based on Welch t test. A P value of less than 0.05 was
considered statistically significant.
RESULTS
The mean dose of nicotinamide at the end of the 12-
week treatment period was 1080 ± 370 mg/day. The min-
imum dose of nicotinamide was 500 mg/day (7.9 mg/kg
body weight/day) and the maximum was 1750 mg/day
(33.3 mg/kg body weight/day). Compliance was con-
firmed in all cases. No significant changes were observed
in PCR with nicotinamide treatment (before treatment,
1.1 ± 0.2 g/kg/day vs. after treatment, 1.1 ± 0.2 g/kg/day).
The blood NAD concentration increased from 9.3 ±
1.9 nmol/105 erythrocytes to 13.2 ± 5.3 nmol/105 erythro-
cytes with nicotinamide treatment (P < 0.01) (Fig. 1). The
doses of nicotinamide were significantly correlated with
blood NAD concentrations (r = 0.805, P < 0.0001). After
the posttreatment washout period, the blood NAD level
decreased significantly to 8.4 ± 2.7 nmol/105 erythrocytes
(P < 0.005). There was no significant difference in the
NAD concentration between the pretreatment washout
period and the posttreatment washout period.
Serum phosphorus levels changed significantly with
nicotinamide treatment (Fig. 2). Serum phosphorus levels
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Fig. 1. Effect of nicotinamide on blood nicotinamide adenine dinu-
cleotide (NAD) concentration in hemodialysis patients. −2 weeks in-
dicates the start of pretreatment washout. ∗vs. 0 week, P < 0.01.
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Fig. 2. Changes in serum phosphorus levels with nicotinamide treat-
ment in hemodialysis patients. ∗vs. 0 week, P < 0.001; ∗∗vs. 0 week, P <
0.01.
increased from 5.4 ± 1.5 mg/dL before the pretreatment
washout period to 6.9 ± 1.5 mg/dL after the pretreatment
washout period. Serum phosphorus levels decreased im-
mediately after the start of nicotinamide treatment and
continued to decrease until the cessation of treatment.
Serum phosphorus levels decreased from 6.9 ± 1.5 mg/dL
to 5.4 ± 1.3 mg/dL during the 12 weeks of nicotinamide
treatment (P < 0.0001). After the posttreatment washout,
serum phosphorus levels increased significantly to 6.7 ±
1.6 mg/dL (P < 0.0001). Reductions in serum phospho-
rus levels were comparable between vitamin D users and
nonvitamin D users.
Serum calcium levels decreased from 9.1 ± 0.8 mg/dL
before the pretreatment washout period to 8.7 ± 0.7 mg/
dL after the pretreatment washout period (P < 0.0001)
(Fig. 3). Serum calcium levels were unchanged during the
12 weeks of nicotinamide treatment (8.8 ± 0.7 mg/dL,
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Fig. 3. Serum calcium levels in relation to nicotinamide treatment in
hemodialysis patients.
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Fig. 4. Effect of nicotinamide treatment on calcium-phosphorus prod-
uct in hemodialysis patients. ∗vs. 0 week, P < 0.0001; ∗∗ vs. 0 week, P <
0.01.
P = 0.4230) and remained the same after the 2-week
posttreatment washout period (8.8 ± 0.7 mg/dL). Serum
calcium levels were similar between vitamin D users and
nonvitamin D users.
The calcium-phosphate product increased significantly
from 48.4 ± 13.6 mg2/dL2 to 59.8 ± 14.5 mg2/dL2 at the
end of the pretreatment washout period (P < 0.0001)
(Fig. 4). A calcium-phosphorus product decreased im-
mediately and significantly to 47.3 ± 13.4 mg2/dL2 during
the 12 weeks of nicotinamide treatment (P < 0.0001).
With the cessation of nicotinamide, the serum calcium-
phosphorus product increased gradually, reaching 58.7 ±
16.1 mg2/dL2 after the 2-week posttreatment washout pe-
riod (P < 0.0001).
Median serum iPTH levels over the course of the study
are shown in Figure 5. Median serum iPTH levels in-
creased with the pretreatment washout from 130.0 (32.8
to 394.0) pg/mL to 200.0 (92.5 to 535.0) pg/mL (P < 0.05).
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Fig. 5. Box and whisker plots showing serum intact parathyroid hor-
mone (iPTH) levels in nicotinamide-treated hemodialysis patients. ∗vs.
−2 weeks, P < 0.05; ∗∗vs. 4 weeks, P < 0.05.
With nicotinamide treatment, median serum iPTH lev-
els reached 230.0 (90.8 to 582.0) pg/mL on week 4 and
decreased, reaching 150.0 (57.6 to 518.0) pg/mL by the
end of the 12 weeks of treatment (P < 0.05). After
the 2-week posttreatment washout period, median serum
iPTH levels were again increased to 220.0 (97.2 to 570.0)
pg/mL. Median iPTH levels decreased with nicotinamide
treatment in both vitamin D users and nonvitamin
D users. Median serum iPTH levels after nicotinamide
treatment did not differ significantly from those before
the pretreatment washout. No changes were observed
in serum magnesium concentrations with nicotinamide
treatment. Serum alkaline phosphatase levels decreased
significantly from 173.8 ± 79.3 IU/L to 159.3 ± 68.4 IU/L
(P < 0.01) at 6 weeks and to 159.2 ± 58.6 IU/L (P < 0.01)
at 12 weeks after the start of nicotinamide treatment and
then increased significantly to 166.1 ± 59.8 IU/L (P <
0.05) at 2 weeks after the cessation of nicotinamide.
Serum high-density lipoprotein (HDL) cholesterol lev-
els increased significantly from 47.4 ± 14.9 mg/dL before
the pretreatment washout period to 67.2 ± 22.3 mg/dL
(P < 0.0001) after the 12 weeks of nicotinamide treat-
ment. In contrast, serum low-density lipoprotein (LDL)
cholesterol levels decreased from 78.9 ± 18.8 mg/dL to
70.1 ± 25.3 mg/dL (P < 0.01). There were no changes in
serum total cholesterol levels (before treatment, 160.9 ±
30.3 mg/dL vs. after treatment, 161.6 ± 33.9 mg/dL) or
in serum triglyceride levels (before treatment, 145.7 ±
82.2 mg/dL vs. after treatment, 131.4 ± 69.6 mg/dL)
throughout the study period. Changes in serum HDL
cholesterol levels correlated significantly with changes in
NAD concentrations (r = 0.512, P < 0.01).
There were no significant changes in other labora-
tory values during nicotinamide treatment. Serum albu-
min and total serum proteins did not change significantly
during the study. Adverse events possibly related to treat-
ment included diarrhea (five patients, 7.8%) and throm-
bocytopenia (one patient, 1.6%). The platelet count of
the patient with thrombocytopenia decreased from 16.8×
104/lL to 8.3 × 104/lL. Two weeks after discontinuance
of nicotinamide, the platelet count increased to 18.0 ×
104/lL. There were no changes in his erythrocyte or
leucocyte count during nicotinamide treatment. All six
patients with adverse effects had received more than
1500 mg/day of nicotinamide. The diarrhea and throm-
bocytopenia disappeared when the nicotinamide was re-
duced or discontinued.
DISCUSSION
Hyperphosphatemia is an important risk factor for the
development of ectopic calcification and cardiovascular
changes in patients undergoing hemodialysis. Although
calcium- or aluminum-based phosphate binders are
usually essential for avoiding hyperphosphatemia in
long-term hemodialysis patients, certain adverse effects
associated with the absorption of calcium and/or
aluminum are inevitable. We showed in the present study
that nicotinamide controls serum phosphorus levels in
hemodialysis patients at levels similar to those achieved
with currently available calcium- or aluminum-based
phosphate binders.
A novel calcium- and aluminum-free phosphate
binder, poly[allylamine hydrochloride] (RenaGel, Gel-
Tex Pharmaceuticals, Inc., Waltham, MA, USA), was re-
cently reported to reduce serum phosphorus and iPTH
concentrations without significant changes in serum cal-
cium levels [15–17]. Total serum cholesterol and LDL
cholesterol levels were also shown to be significantly re-
duced in RenaGel-treated patients without a reduction
in HDL cholesterol [15–17].
Nicotinamide, a metabolite of nicotinic acid, stimulates
biosynthesis of NAD, inhibits catabolism of NAD, and in-
creases the ratio of NAD (oxidized) to NADH (reduced)
[10]. The mechanism by which nicotinamide lowers serum
phosphorus levels remains unknown. NAD is proposed to
be an intracellular regulator of sodium-dependent phos-
phate transport [10]. Nicotinamide has been shown in rats
to increase the renal cortical NAD concentration, inhibit
phosphate uptake by brush border membrane vesicles of
the renal proximal tubules in the rat kidney, and increase
phosphate excretion in thyroparathyroidectomized rats
[9, 10]. Intestinal phosphate transport is reported to occur
by a sodium-independent, nonsaturable process and an
active, sodium-dependent component of phosphate ab-
sorption in the duodenum and jejunum [18]. Katai et al
[11] showed that nicotinamide inhibits phosphate uptake
in the brush border membrane of rat small intestine. Fur-
thermore, nicotinamide, apart from its inhibitory effect
on poly(ADP-ribose) polymerase (PARP)-1 and its abil-
ity to restore intracellular NAD+ pools, has recently been
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suggested to act against the pathogenic process leading
to insulin-dependent diabetes mellitus (IDDM). A re-
cent meta-analysis showed nicotinamide, when given at
the time of IDDM diagnosis, to have a protective effect
on residual cell function of the pancreas as assessed by
C-peptide secretion [19]. It is probable that nicotinamide
improves insulin secretion and consequently decreases
serum phosphorus levels by shifting phosphorus from the
extracellular to the intracellular space.
Nicotinamide significantly reduced serum phosphorus
levels in hemodialysis patients in the present study. Mean
serum phosphorus levels decreased significantly during
the 12 weeks of nicotinamide treatment and increased
significantly to pretreatment levels after the 2-week post-
treatment washout, suggesting the serum phosphorus-
lowering effect to be due to nicotinamide. The onset of
nicotinamide action was relatively rapid; the substantial
reduction in serum phosphorus levels occurred within 2
weeks. This study proved that the serum phosphorus–
lowering ability of nicotinamide is nearly equivalent to
that of calcium-based phosphate binders.
Serum calcium levels declined after the pretreatment
washout in our study, probably due to the removal
of calcium carbonate. Nicotinamide treatment did not
change serum calcium levels during the 12 weeks. The
risk of vascular calcification increases with increases in
serum calcium-phosphorus product. The mean increase
in serum calcium-phosphorus product we observed after
the pretreatment washout along with the remarkable re-
duction to below prewashout levels indicates that nicoti-
namide can reduce the risk of vascular calcification in
hemodialysis patients.
Several investigators have shown that increased serum
phosphorus levels increase the synthesis and secretion of
PTH [20–22]. Evidence exists for a direct role of serum
phosphorus as a regulator of parathyroid gland function
[23]. In the present study, median serum iPTH levels grad-
ually decreased after the start of nicotinamide treatment
and showed significant reduction after 12 weeks of treat-
ment. The increase in serum phosphorus and the decrease
in serum calcium with pretreatment washout stimulated
a corresponding increase in median serum iPTH levels.
The decline in serum iPTH levels during the second half
of nicotinamide treatment was associated with the decline
in serum phosphorus.
Nicotinamide treatment significantly increased serum
HDL cholesterol and decreased LDL cholesterol in our
subjects. Shepherd et al [24] reported that nicotinic acid
elevates the HDL2-to-HDL3 ratio because of a great in-
crease in the absolute level of circulating HDL2 and a
small absolute decrease in circulating HDL3. Cardiovas-
cular diseases, including myocardial infarction, sudden
death, and stroke, collectively account for approximately
50% of the mortality of ESRD patients [25, 26]. There
are multiple abnormalities in the lipid profi1e of ESRD
patients, and these may contribute to the high inci-
dence of atherosclerosis [27]. Controlled clinical trials will
ultimately determine whether an increase in HDL
cholesterol will be of benefit to ESRD patients with
atherosclerosis.
Nicotinamide treatment has a few adverse effects, in-
cluding the possible occurrence of gastrointestinal disor-
ders such as diarrhea. One patient showed a statistically
significant decrease in platelet count during nicoti-
namide treatment. After the washout period, however,
the platelet count returned to the pretreatment level.
Nicotinamide has been used at 1500 mg/day to 3000 mg/
day without adverse effects for protection of beta cells
from end-stage destruction in patients with recent-onset
IDDM [28]. However, we used a mean dose of 1080
mg/day. Rutkowski et al [29] reported recently that
serum N-methyl-2-pyridine-5-carboxamide (2-PY), an
end product of NAD degradation, was elevated in
hemodialysis patients and that nicotinamide inhibited
PARP-1 activity in vitro. In the present study, however,
intracellular NAD levels in hemodialysis patients (9.3
nmol/105 erythrocytes) were nearly the same as levels in
healthy subjects (9.0 nmol/105 erythrocytes) [12], suggest-
ing that intracellular 2-PY concentrations may not be in-
creased in chronic renal failure patients. Nicotinamide is a
well-known inhibitor of PARP-1. Activation of PARP-1
has been implicated in the pathogenesis of stroke, my-
ocardial ischemia, diabetes, cardiovascular dysfunction,
shock, central nervous system injury, and various other
forms of inflammation. Therefore, inhibition of PARP-1
by pharmacological agents may prove useful in the treat-
ment of these diseases. Although blood NAD concen-
trations were increased up to 13.2 nmol/105 erythrocytes
after nicotinamide administration in our study, it is not
clear whether this concentration of intracellular NAD
can inhibit PARP-1 activity. Further studies on adverse
effects of long-term administration of nicotinamide are
needed.
CONCLUSION
Nicotinamide may provide an alternative for con-
trolling hyperphosphatemia and hyperparathyroidism in
hemodialysis patients.
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